Famotidine
Duexis, Pepcid (famotidine) is a small molecule pharmaceutical. Famotidine was first approved as Pepcid on 1986-10-15. It is used to treat duodenal ulcer, dyspepsia, gastroesophageal reflux, heartburn, and helicobacter infections amongst others in the USA. The pharmaceutical is active against histamine H2 receptor.
Download report
Favorite
COVID-19
Commercial
Trade Name
FDA
EMA
Pepcid ac (generic drugs available since 2001-04-16, discontinued: Fluxid, Pepcid, Pepcid rpd)
CombinationsDuexis, Pepcid complete (generic drugs available since 2001-04-16)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
duexis | New Drug Application | 2021-06-08 |
maximum strength acid reducer | ANDA | 2023-06-15 |
pepcid ac | New Drug Application | 2023-04-24 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
duodenal ulcer | EFO_0004607 | D004381 | K26 |
dyspepsia | EFO_0008533 | D004415 | K30 |
gastroesophageal reflux | EFO_0003948 | D005764 | K21 |
heartburn | — | D006356 | R12 |
helicobacter infections | EFO_1000961 | D016481 | — |
peptic esophagitis | EFO_1001095 | D004942 | — |
stomach ulcer | — | D013276 | K25 |
urticaria | EFO_0005531 | D014581 | L50 |
zollinger-ellison syndrome | — | D015043 | E16.4 |
Agency Specific
FDA
EMA
No data
HCPCS
Code | Description |
---|---|
S0028 | Injection, famotidine, 20 mg |
Clinical
Clinical Trials
90 clinical trials
View more details

Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Covid-19 | D000086382 | U07.1 | 1 | 7 | 3 | 2 | 2 | 14 | |
Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | 1 | 2 | 2 | 1 | 1 | 5 |
Hiv infections | D015658 | EFO_0000764 | B20 | 2 | — | — | 1 | — | 3 |
Heartburn | D006356 | R12 | 2 | — | — | 1 | — | 3 | |
Acute coronary syndrome | D054058 | EFO_0005672 | — | — | — | 2 | — | 2 | |
Inferior wall myocardial infarction | D056989 | EFO_1000983 | — | — | — | 2 | — | 2 | |
Schizophrenia | D012559 | EFO_0000692 | F20 | — | 1 | 1 | 1 | — | 2 |
Peptic ulcer | D010437 | HP_0004398 | K27 | — | — | — | 2 | — | 2 |
Ulcer | D014456 | MPATH_579 | — | — | 1 | 1 | — | 2 | |
Anesthesia | D000758 | — | — | — | 1 | — | 1 |
Show 9 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | 1 | — | 1 | 2 |
Lymphoma | D008223 | C85.9 | — | — | 1 | — | — | 1 | |
Esophagitis | D004941 | HP_0100633 | K20 | — | — | 1 | — | — | 1 |
Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Laryngomalacia | D055092 | HP_0001601 | 1 | 1 | — | — | 1 | 2 | |
Stroke | D020521 | EFO_0000712 | I63.9 | — | 1 | — | — | — | 1 |
Brain edema | D001929 | EFO_1000845 | G93.6 | — | 1 | — | — | — | 1 |
Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | 1 | — | — | — | 1 |
Squamous cell carcinoma of head and neck | D000077195 | — | 1 | — | — | — | 1 | ||
Eosinophilic esophagitis | D057765 | EFO_0004232 | K20.0 | — | 1 | — | — | — | 1 |
Pulmonary arterial hypertension | D000081029 | — | 1 | — | — | — | 1 | ||
Dyskinesias | D020820 | G24 | — | 1 | — | — | — | 1 | |
Immunoglobulin g4-related disease | D000077733 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | 18 | — | — | — | 2 | 20 | ||
Drug interactions | D004347 | 2 | — | — | — | — | 2 | ||
Biological availability | D001682 | 2 | — | — | — | — | 2 | ||
Neoplasms | D009369 | C80 | 2 | — | — | — | — | 2 | |
Autonomic nervous system diseases | D001342 | EFO_0009532 | G90 | 1 | — | — | — | — | 1 |
Fibrosis | D005355 | 1 | — | — | — | — | 1 | ||
Psoriasis | D011565 | EFO_0000676 | L40 | 1 | — | — | — | — | 1 |
Colorectal neoplasms | D015179 | 1 | — | — | — | — | 1 | ||
Non-small-cell lung carcinoma | D002289 | 1 | — | — | — | — | 1 | ||
Melanoma | D008545 | 1 | — | — | — | — | 1 |
Show 1 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Rhytidoplasty | D015361 | — | — | — | — | 1 | 1 | ||
Vomiting | D014839 | HP_0002013 | R11.1 | — | — | — | — | 1 | 1 |
Exercise | D015444 | EFO_0000483 | — | — | — | — | 1 | 1 | |
Respiratory sounds | D012135 | HP_0010307 | R06.1 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | FAMOTIDINE |
INN | famotidine |
Description | Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.
|
Classification | Small molecule |
Drug class | H2-receptor antagonists (cimetidine type) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | NC(N)=Nc1nc(CSCC/C(N)=N/S(N)(=O)=O)cs1 |
Identifiers
PDB | — |
CAS-ID | 76824-35-6 |
RxCUI | 4278 |
ChEMBL ID | CHEMBL902 |
ChEBI ID | 4975 |
PubChem CID | 5702160 |
DrugBank | DB00927 |
UNII ID | 5QZO15J2Z8 (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
Duexis - Horizon Therapeutics Public
$
€
£
₣

Mock data
Subscribe for the real data
Subscribe for the real data

Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:

Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,334 documents
View more details
Safety
Black-box Warning
Black-box warning for: Duexis
Adverse Events
Top Adverse Reactions

Mock data
Subscribe for the real data
Subscribe for the real data
78,867 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more